Evaxion names Dr Helen Tayton‑Martin Chief Executive Officer

Rhea-AI Filing Summary

Evaxion A/S reported a leadership change via a Form 6-K. On October 27, 2025, the company issued a press release titled “Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer,” furnished as Exhibit 99.1.

The report is also incorporated by reference into Evaxion’s effective registration statements on Forms S-8, F-1, and F-3, ensuring the press release becomes part of those filings. The submission was signed by Interim Chief Executive Officer Birgitte Rønø.

Insights

Corporate governance analyst

CEO appointment disclosed; governance update without financial details.

Evaxion A/S furnished a press release announcing the appointment of Dr Helen Tayton-Martin as Chief Executive Officer. The information is provided on a Form 6-K, which communicates material updates for foreign private issuers.

The 6-K incorporates the press release into existing registration statements, aligning disclosures across offering documents. Any strategic or operational effects will depend on subsequent company communications and future filings.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number: 001-39950

Evaxion A/S
(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]      Form 40-F [   ]

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Press Release

On October 27, 2025, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits

Exhibit No.		Description
99.1		Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Evaxion A/S
			(Registrant)
Date: October 27, 2025		By:	/s/ Birgitte Rønø
			Birgitte Rønø
			Interim Chief Executive Officer

FAQ

What did EVAX announce in its Form 6-K?

Evaxion A/S announced the appointment of Dr Helen Tayton-Martin as its new Chief Executive Officer, furnished as Exhibit 99.1.

When did EVAX issue the CEO appointment press release?

The press release was issued on October 27, 2025.

Which exhibit contains the CEO announcement for EVAX?

The CEO announcement is included as Exhibit 99.1.

What type of company is Evaxion A/S (EVAX)?

Evaxion is a clinical-stage TechBio company developing AI-Immunology™ powered vaccines.

Does this 6-K affect EVAX’s registration statements?

Yes. The report is incorporated by reference into Evaxion’s S-8, F-1, and F-3 registration statements listed in the filing.

Who signed the EVAX 6-K submission?

It was signed by Birgitte Rønø, Interim Chief Executive Officer.